Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The making of leukemia

  • González-Herrero, Inés
  • Rodríguez-Hernández, Guillermo
  • Luengas-Martínez, Andrea
  • Isidro‑Hernández, Marta
  • Jiménez, Rafael
  • García-Cenador, Begoña
  • García-Criado, Francisco Javier
  • Sánchez García, Isidro
  • Vicente-Dueñas, Carolina
© 2018 by the authors., Due to the clonal nature of human leukemia evolution, all leukemic cells carry the same leukemia-initiating genetic lesions, independently of the intrinsic tumoral cellular heterogeneity. However, the latest findings have shown that the mode of action of oncogenes is not homogeneous throughout the developmental history of leukemia. Studies on different types of hematopoietic tumors have shown that the contribution of oncogenes to leukemia is mainly mediated through the epigenetic reprogramming of the leukemia-initiating target cell. This driving of cancer by a malignant epigenetic stem cell rewiring is, however, not exclusive of the hematopoietic system, but rather represents a common tumoral mechanism that is also at work in epithelial tumors. Tumoral epigenetic reprogramming is therefore a new type of interaction between genes and their target cells, in which the action of the oncogene modifies the epigenome to prime leukemia development by establishing a new pathological tumoral cellular identity. This reprogramming may remain latent until it is triggered by either endogenous or environmental stimuli. This new view on the making of leukemia not only reveals a novel function for oncogenes, but also provides evidence for a previously unconsidered model of leukemogenesis, in which the programming of the leukemia cellular identity has already occurred at the level of stem cells, therefore showing a role for oncogenes in the timing of leukemia initiation, We are indebted to all members of our groups for useful discussions and for their critical reading of the manuscript. Research in C.V.-D. group is partially supported by FEDER, “Miguel Servet” Grant (CP14/00082-AES 2013–2016) from the Instituto de Salud Carlos III (Ministerio de Economía y Competitividad), “Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III” (PI17/00167) and by the Lady Tata International Award for Research in Leukaemia 2016–2017. Research in I.S.G. group is partially supported by FEDER and by MINECO (SAF2012-32810, SAF2015-64420-R and Red de Excelencia Consolider OncoBIO SAF2014-57791-REDC), and by Junta de Castilla y León (UIC-017, and CSI001U16). I.S.G. lab is a member of the EuroSyStem and the DECIDE Network funded by the European Union under the FP7 program. I.S.G. has been supported by the German Carreras Foundation (DJCLS R13/26).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Infectious triggers and novel therapeutic opportunities in childhood B cell leukaemia

  • Cobaleda, César
  • Vicente-Dueñas, Carolina
  • Sánchez García, Isidro
B cell acute lymphoblastic leukaemia (B-ALL) is the most common form of childhood cancer. Although treatment has advanced remarkably in the past 50 years, it still fails in ~20% of patients. Recent studies revealed that more than 5% of healthy newborns carry preleukaemic clones that originate in utero, but only a small percentage of these carriers will progress to overt B-ALL. The drivers of progression are unclear, but B-ALL incidence seems to be increasing in parallel with the adoption of modern lifestyles. Emerging evidence shows that a major driver for the conversion from the preleukaemic state to the B-ALL state is exposure to immune stressors, such as infection. Here, we discuss our current understanding of the environmental triggers and genetic predispositions that may lead to B-ALL, highlighting lessons from epidemiology, the clinic and animal models, and identifying priority areas for future research., Research at C.C.’s laboratory was partially supported by the European Regional Development Fund (FEDER)/MINECO (SAF2017-83061-R), Fundación Ramón Areces and a research contract with Fundación Síndrome de Wolf-Hirschhorn o 4p-. Institutional grants from Fundación Ramón Areces and Banco de Santander to Centro de Biología Molecular Severo Ochoa are also acknowledged. The C.C. and C.V.-D. laboratories are members of the EU COST Action LEGEND (CA16223). Research in the C.V.-D. group is partially supported by an FEDER Miguel Servet grant (CPII19/00024 — AES 2017-2020) from Instituto de Salud Carlos III (Ministerio de Economía y Competitividad), Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III (PI17/00167). Research in the I.S.-G. group is partially supported by the FEDER and by MINECO/FEDER (SAF2015-64420-R), MCIU/AEI/FEDER (RTI2018-093314-B-I00), Junta de Castilla y León (UIC-017, CSI001U16, CSI234P18 and CSI144P20), the German Carreras Foundation (DJCLS 07R/2019) and Fundacion Unoentrecienmil (CUNINA project). The I.S.-G. laboratory is a member of EuroSyStem and the DECIDE Network funded by the European Union under the Seventh Framework Programme. C.V.-D. and I.S.-G. have been supported by the German Federal Office for Radiation Protection (BfS) (FKZ: 3618S32274).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Childhood B-Cell Preleukemia Mouse Modeling

  • Isidro‑Hernández, Marta
  • Alemán-Arteaga, Silvia
  • Casado-García, Ana
  • Ruiz-Corzo, Belén
  • Riesco, Susana
  • Prieto-Matos, Pablo
  • Martínez-Cano, Jorge
  • Sánchez, Lucía
  • Cobaleda, César
  • Sánchez García, Isidro
  • Vicente-Dueñas, Carolina
Leukemia is the most usual childhood cancer, and B-cell acute lymphoblastic leukemia (B-ALL) is its most common presentation. It has been proposed that pediatric leukemogenesis occurs through a “multi-step” or “multi-hit” mechanism that includes both in utero and postnatal steps. Many childhood leukemia-initiating events, such as chromosomal translocations, originate in utero, and studies so far suggest that these “first-hits” occur at a far higher frequency than the incidence of childhood leukemia itself. The reason why only a small percentage of the children born with such preleukemic “hits” will develop full-blown leukemia is still a mystery. In order to better understand childhood leukemia, mouse modeling is essential, but only if the multistage process of leukemia can be recapitulated in the model. Therefore, mouse models naturally reproducing the “multi-step” process of childhood B-ALL will be essential to identify environmental or other factors that are directly linked to increased risk of disease., Research in CV-D group has been funded by Instituto de Salud Carlos III (ISCIII), through a “Miguel Servet Grant” (CPII19/00024-AES 2017–2020); co-funded by the European Union. Research in IS-G group is partially supported by FEDER and by SAF2015-64420-R MINECO/FEDER, UE, RTI2018-093314-B-I00 MCIU/AEI/FEDER, UE, by PID2021-122185OB-I00 MCIU/AEI/FEDER, UE, and by Junta de Castilla y León (UIC-017, CSI001U16, CSI234P18, and CSI144P20). IS-G have been supported by the Fundacion Unoentrecienmil (CUNINA project). CC and IS-G have been supported by the Fundación Científica de la Asociación Española contra el Cáncer (PRYCO211305SANC). Research at CC’s laboratory was partially supported by Ministerio de Ciencia e Innovación/AEI/FEDER (PID2021-122787OB-I00), FEDER MINECO (SAF2017-83061-R), the “Fundación Ramón Areces” and a Research Contract with the “Fundación Síndrome de Wolf-Hirschhorn o 4p-”. Institutional grants from the “Fundación Ramón Areces” and “Banco de Santander” to the CBMSO are also acknowledged. J.M.-C. is the recipient of a UAM FPU fellowship. AC-G (CSI067-18) and MI-H (CSI021-19) are supported by FSE-Conserjería de Educación de la Junta de Castilla y León 2019 and 2020 (ESF—European Social Fund) fellowship, respectively. SA-A is supported by an Ayuda para Contratos predoctorales para la formación de doctores (PRE2019-088887). L.S. is supported by a scholarship from University of Salamanca co-financed by Banco Santander and ESF.